PTC Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:PTCT)

Analyst Price Target for PTCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$64.90

▲ +32.96% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for PTC Therapeutics in the last 3 months. The average price target is $64.90, with a high forecast of $86.00 and a low forecast of $47.00. The average price target represents a 32.96% upside from the last price of $48.81.

Buy

The current consensus among 12 contributing investment analysts is to buy stock in PTC Therapeutics. This rating has held steady since August 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/21/2019

0 strong buy ratings
5 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

1/19/2020

0 strong buy ratings
4 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/18/2020

0 strong buy ratings
4 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/17/2020

0 strong buy ratings
6 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

10/15/2020

0 strong buy ratings
8 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

1/13/2021

0 strong buy ratings
8 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

3/14/2021

0 strong buy ratings
7 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

4/13/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
3/29/2021	Royal Bank of Canada	Upgrade	Underperform ➝ Sector Perform	$47.00	Medium	i
2/26/2021	Cantor Fitzgerald	Lower Price Target	Overweight	$81.00 ➝ $75.00	High	i
2/12/2021	Bank of America	Downgrade	Buy ➝ Neutral		Low	i
1/5/2021	Smith Barney Citigroup	Upgrade	Neutral ➝ Buy		N/A	i
1/5/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Neutral ➝ Buy	$67.00 ➝ $85.00	N/A	i
12/16/2020	Raymond James	Boost Price Target	Outperform	$63.00 ➝ $70.00	Medium	i
11/30/2020	Royal Bank of Canada	Downgrade	Sector Perform ➝ Underperform	$45.00	High	i
10/30/2020	Smith Barney Citigroup	Downgrade	Buy ➝ Neutral		Medium	i
10/30/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Downgrade	Buy ➝ Neutral		Medium	i
10/30/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$75.00 ➝ $67.00	High	i
10/28/2020	UBS Group	Initiated Coverage	Neutral	$55.00	Medium	i
10/7/2020	JPMorgan Chase & Co.	Upgrade	Neutral ➝ Overweight	$71.00	High	i
9/23/2020	Raymond James	Reiterated Rating	Buy		Medium	i
8/24/2020	Raymond James	Initiated Coverage	Outperform	$63.00	High	i
8/11/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$85.00 ➝ $75.00	Low	i Rating by Alethia Young at Cantor Fitzgerald
8/10/2020	Bank of America	Lower Price Target	Buy	$60.00 ➝ $58.00	Medium	i
8/10/2020	Credit Suisse Group	Lower Price Target	Neutral	$53.00 ➝ $52.00	Low	i Rating by Martin Auster at Credit Suisse Group AG
7/20/2020	Cowen	Reiterated Rating	Hold	$50.00	High	i Rating by Joseph Thome at Cowen Inc
7/20/2020	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$53.00	High	i
7/20/2020	SunTrust Banks	Boost Price Target	Buy	$75.00 ➝ $86.00	High	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
5/1/2020	SunTrust Banks	Lower Price Target	Buy	$78.00 ➝ $75.00	Medium	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
4/28/2020	William Blair	Reiterated Rating	Buy		Low	i
4/9/2020	Citigroup	Upgrade	Neutral ➝ Buy	$71.00 ➝ $67.00	High	i
4/8/2020	Cantor Fitzgerald	Lower Price Target	Overweight	$86.00 ➝ $85.00	Medium	i Rating by Alethia Young at Cantor Fitzgerald
4/8/2020	Royal Bank of Canada	Reiterated Rating	Hold	$45.00	High	i
3/4/2020	Barclays	Reiterated Rating	Hold	$51.00	High	i
3/3/2020	Cantor Fitzgerald	Reiterated Rating	Positive ➝ Overweight	$81.00 ➝ $86.00	High	i Rating by Alethia Young at Cantor Fitzgerald
3/2/2020	Cowen	Reiterated Rating	Hold		High	i
2/20/2020	Citigroup	Downgrade	Buy ➝ Neutral	$55.00 ➝ $71.00	High	i Rating by Joel Beatty at Citigroup Inc.
2/20/2020	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$63.00 ➝ $60.00	High	i Rating by Brian Abrahams at Royal Bank of Canada
2/6/2020	SunTrust Banks	Reiterated Rating	Buy	$78.00	Medium	i Rating by Robyn Karnauskas at SunTrust Banks, Inc.
2/6/2020	Cowen	Reiterated Rating	Hold		High	i
1/23/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$60.00 ➝ $81.00	Low	i Rating by Alethia Young at Cantor Fitzgerald
1/15/2020	Cantor Fitzgerald	Reiterated Rating	Buy	$60.00	Medium	i Rating by Alethia Young at Cantor Fitzgerald
12/5/2019	Royal Bank of Canada	Reiterated Rating	Outperform	$58.00	Medium	i Rating by Brian Abrahams at Royal Bank of Canada
11/26/2019	William Blair	Reiterated Rating	Buy		Low	i
11/12/2019	SunTrust Banks	Initiated Coverage	Buy	$78.00	Low	i
10/31/2019	Credit Suisse Group	Reiterated Rating	Buy	$54.00	Low	i
10/30/2019	Cowen	Reiterated Rating	Hold		High	i
9/26/2019	Citigroup	Set Price Target	Buy	$62.00	High	i Rating by Joel Beatty at Citigroup Inc.
9/24/2019	Royal Bank of Canada	Reiterated Rating	Buy		High	i Rating by Brian Abrahams at Royal Bank of Canada
8/12/2019	Barclays	Reiterated Rating	Hold	$43.00	Low	i
5/13/2019	Bank of America	Upgrade	Neutral ➝ Buy	$43.00 ➝ $49.00	Low	i
5/8/2019	Cowen	Reiterated Rating	Hold		High	i
5/3/2019	Citigroup	Set Price Target	Buy	$59.00	Low	i Rating by Joel Beatty at Citigroup Inc.
5/2/2019	Cowen	Reiterated Rating	Hold		High	i
4/11/2019	Sanford C. Bernstein	Initiated Coverage	Outperform	$48.00	Low	i
2/28/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$61.00	High	i
1/29/2019	Credit Suisse Group	Set Price Target	Buy	$51.00	High	i Rating by Martin Auster at Credit Suisse Group AG
1/7/2019	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
1/7/2019	Credit Suisse Group	Reiterated Rating	Buy	$55.00	High	i Rating by Martin Auster at Credit Suisse Group AG
1/7/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$61.00	High	i
11/12/2018	Cantor Fitzgerald	Lower Price Target	Overweight ➝ Overweight	$66.00 ➝ $61.00	High	i
11/6/2018	Royal Bank of Canada	Lower Price Target	Outperform ➝ Outperform	$51.00 ➝ $46.00	High	i
11/6/2018	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$43.00 ➝ $40.00	High	i
11/6/2018	William Blair	Reiterated Rating	Buy		High	i Rating by Raju Prasad at William Blair
11/5/2018	Credit Suisse Group	Set Price Target	Buy	$55.00	High	i Rating by Martin Auster at Credit Suisse Group AG
10/3/2018	Bank of America	Upgrade	Underperform ➝ Neutral		High	i
10/3/2018	Credit Suisse Group	Set Price Target	Buy	$55.00	Medium	i Rating by Martin Auster at Credit Suisse Group AG
10/3/2018	William Blair	Reiterated Rating	Buy		High	i Rating by R. Prasad at William Blair
10/1/2018	Cantor Fitzgerald	Initiated Coverage	Overweight ➝ Overweight	$66.00	Medium	i
9/28/2018	JPMorgan Chase & Co.	Boost Price Target	Positive ➝ Neutral	$51.00	Low	i
9/5/2018	Credit Suisse Group	Boost Price Target	Outperform ➝ Outperform	$49.00 ➝ $53.00	Low	i
8/8/2018	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$40.00 ➝ $43.00	High	i
7/31/2018	Bank of America	Boost Price Target	Underperform ➝ Underperform	$27.00 ➝ $31.00	High	i
7/24/2018	Citigroup	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $50.00	Low	i Rating by Joel Beatty at Citigroup Inc.
7/19/2018	Credit Suisse Group	Initiated Coverage	Outperform	$49.00	High	i
6/20/2018	Barclays	Upgrade	Underweight ➝ Equal Weight		High	i
6/18/2018	William Blair	Upgrade	Market Perform ➝ Outperform		High	i Rating by Raju Prasad at William Blair
6/18/2018	Royal Bank of Canada	Upgrade	Sector Perform ➝ Outperform	$11.00	High	i
5/10/2018	William Blair	Reiterated Rating	Hold		High	i Rating by Raju Prasad at William Blair
4/3/2018	Barclays	Downgrade	Equal Weight ➝ Underweight	$24.00 ➝ $26.00	High	i
3/7/2018	Barclays	Reiterated Rating	Equal Weight ➝ Equal Weight	$18.00 ➝ $24.00	High	i
3/7/2018	William Blair	Reiterated Rating	Hold		High	i
2/21/2018	Citigroup	Boost Price Target	Buy ➝ Buy	$24.00 ➝ $35.00	High	i
1/30/2018	Credit Suisse Group	Reiterated Rating	Buy	$28.00	Medium	i
1/29/2018	Royal Bank of Canada	Initiated Coverage	Sector Perform ➝ Sector Perform		High	i Rating by Matthew Eckler at Royal Bank of Canada
1/23/2018	Barclays	Reiterated Rating	Hold		Low	i
11/24/2017	JPMorgan Chase & Co.	Boost Price Target	Underweight ➝ Neutral	$15.00	N/A	i
11/16/2017	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$15.00	N/A	i
10/26/2017	Bank of America	Downgrade	Neutral ➝ Underperform		N/A	i
10/25/2017	Cowen	Reiterated Rating	Hold		N/A	i
10/25/2017	Royal Bank of Canada	Set Price Target	Hold	$15.00	N/A	i Rating by Matthew Eckler at Royal Bank of Canada
10/9/2017	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$23.00 ➝ $15.00	N/A	i
9/29/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform ➝ Sector Perform		High	i Rating by Matthew Eckler at Royal Bank of Canada
9/29/2017	Barclays	Lower Price Target	Equal Weight ➝ Equal Weight	$22.00 ➝ $15.00	High	i
9/27/2017	Citigroup	Reiterated Rating	Buy	$28.00	Low	i Rating by Joel Beatty at Citigroup Inc.
9/26/2017	Credit Suisse Group	Reiterated Rating	Outperform	$25.00	High	i
9/26/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral		High	i
9/8/2017	Barclays	Reiterated Rating	Hold	$22.00	Low	i
8/23/2017	William Blair	Initiated Coverage	Mkt Perform ➝ Market Perform	$17.00	Low	i Rating by R. Prasad at William Blair
7/20/2017	Citigroup	Reiterated Rating	Buy	$28.00 ➝ $17.00	High	i Rating by Joel Beatty at Citigroup Inc.
6/30/2017	JPMorgan Chase & Co.	Reiterated Rating	Neutral	$15.00 ➝ $21.00	Low	i
6/7/2017	Citigroup	Set Price Target	Buy	$15.00 ➝ $18.00	High	i
5/8/2017	Royal Bank of Canada	Set Price Target	Hold	$12.00	High	i Rating by Matthew Eckler at Royal Bank of Canada
3/22/2017	Barclays	Reiterated Rating	Equal Weight	$13.00	Medium	i
3/16/2017	Cowen	Reiterated Rating	Hold		High	i
3/16/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$13.00 ➝ $10.00	High	i
3/6/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$13.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
3/6/2017	Credit Suisse Group	Reiterated Rating	Outperform ➝ Positive	$25.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
3/3/2017	Barclays	Downgrade	Overweight ➝ Equal Weight	$20.00 ➝ $13.00	N/A	i
2/16/2017	Credit Suisse Group	Reiterated Rating	Positive		N/A	i Rating by Alethia Young at Credit Suisse Group AG
1/10/2017	Jefferies Financial Group	Reiterated Rating	Hold	$12.00	N/A	i Rating by gena wang at Jefferies Financial Group Inc.
1/2/2017	Royal Bank of Canada	Set Price Target	Hold	$13.00	N/A	i Rating by Michael Yee at Royal Bank of Canada
11/14/2016	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$15.00 ➝ $25.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
11/11/2016	Wedbush	Reiterated Rating	Neutral	$12.00 ➝ $7.00	N/A	i
11/11/2016	Royal Bank of Canada	Boost Price Target	Hold	$13.00	N/A	i Rating by Simos Simeonidis at Royal Bank of Canada
11/11/2016	Royal Bank of Canada	Lower Price Target	Sector Perform	$13.00	N/A	i
11/11/2016	Citigroup	Upgrade	Neutral ➝ Buy	$7.00 ➝ $15.00	N/A	i
11/4/2016	Cowen	Reiterated Rating	Market Perform		N/A	i
11/3/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold	$15.00	N/A	i
11/3/2016	Wedbush	Reiterated Rating	Neutral	$7.00 ➝ $10.00	N/A	i
10/11/2016	Wedbush	Reiterated Rating	Neutral	$10.00	N/A	i
10/11/2016	Credit Suisse Group	Boost Price Target	Neutral	$15.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
10/3/2016	Bank of America	Reiterated Rating	Hold	$15.00	N/A	i
9/22/2016	Jefferies Financial Group	Reiterated Rating	Hold	$7.00	N/A	i Rating by gena wang at Jefferies Financial Group Inc.
8/8/2016	Citigroup	Boost Price Target	Neutral	$8.00 ➝ $9.00	N/A	i
8/7/2016	Cowen	Reiterated Rating	Hold		N/A	i Rating by Ritu Baral at Cowen Inc
8/5/2016	JPMorgan Chase & Co.	Lower Price Target	Neutral	$18.00 ➝ $17.00	N/A	i Rating by Anupam Rama at JPMorgan Chase & Co.
8/5/2016	Credit Suisse Group	Set Price Target	Hold	$6.00	N/A	i Rating by Alethia Young at Credit Suisse Group AG
8/5/2016	Wedbush	Reiterated Rating	Neutral	$10.00	N/A	i Rating by Heather Behanna at Wedbush
8/2/2016	Citigroup	Reiterated Rating	Buy	$48.00	N/A	i
7/26/2016	Wedbush	Lower Price Target	Neutral	$12.00 ➝ $10.00	N/A	i Rating by Heather Behanna at Wedbush
7/26/2016	Credit Suisse Group	Downgrade	Outperform ➝ Neutral		N/A	i Rating by Alethia Young at Credit Suisse Group AG
7/20/2016	Wedbush	Reiterated Rating	Neutral	$12.00	N/A	i Rating by Heather Behanna at Wedbush
5/6/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A	i Rating by Alethia Young at Credit Suisse Group AG
5/6/2016	Jefferies Financial Group	Reiterated Rating	Hold	$8.00	N/A	i Rating by Gena Wang at Jefferies Financial Group Inc.
4/18/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$9.00	N/A	i
4/17/2016	Oppenheimer	Reiterated Rating	Buy	$39.00	N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/17/2016	Cowen	Reiterated Rating	Hold		N/A	i Rating by Ritu Baral at Cowen Inc

(Data available from 4/14/2016 forward)

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) and Emflaza (deflazacort) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients. It is developing Translarna, which is in Phase 2 clinical study for the treatment of nonsense mutation aniridia and nonsense mutation Dravet syndrome/CDKL5; and RG7916 and RO7034067 for the treatment of patients with spinal muscular atrophy, as well as PTC596 and PTC299, a small molecule dihydrooratate dehydrogenase (DHODH) inhibitor that inhibits de novo pyrimidine nucleotide synthesis, which is in Phase 1 clinical development stage to treat cancer patients. The company is also developing gene therapy product candidate that include PTC-AADC for the treatment of Aromatic L-amino acid decarboxylase deficiency. It has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., and the Spinal Muscular Atrophy Foundation to develop and commercialize compounds identified under its spinal muscular atrophy sponsored research program; research collaboration with Massachusetts General Hospital for the treatment of rare genetic disorders resulting from pre-mRNA; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was founded in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $48.81

$47.30

$48.85

50 Day Range

MA: $53.84

$46.80

$60.14

52 Week Range

Now: $48.81

$43.65

$70.82

Volume

1,923 shs

Average Volume

547,068 shs

Market Capitalization

$3.43 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

The following sell-side analysts have issued research reports on PTC Therapeutics in the last twelve months: Bank of America Co., Cantor Fitzgerald, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Cowen Inc, Credit Suisse Group AG, JPMorgan Chase & Co., Raymond James, Royal Bank of Canada, Smith Barney Citigroup, SunTrust Banks, Inc., UBS Group AG, William Blair, and Zacks Investment Research.
View the latest analyst ratings for PTCT.

What is the current price target for PTC Therapeutics?

10 Wall Street analysts have set twelve-month price targets for PTC Therapeutics in the last year. Their average twelve-month price target is $64.90, suggesting a possible upside of 37.2%. SunTrust Banks, Inc. has the highest price target set, predicting PTCT will reach $86.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $47.00 for PTC Therapeutics in the next year.
View the latest price targets for PTCT.

What is the current consensus analyst rating for PTC Therapeutics?

PTC Therapeutics currently has 5 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PTCT will outperform the market and that investors should add to their positions of PTC Therapeutics.
View the latest ratings for PTCT.

What other companies compete with PTC Therapeutics?

Other companies that are similar to PTC Therapeutics include Ono Pharmaceutical, Grifols, Teva Pharmaceutical Industries, Bausch Health Companies, Dr. Reddy's Laboratories, Maravai LifeSciences, Jazz Pharmaceuticals, United Therapeutics, BridgeBio Pharma, Mirati Therapeutics, Ultragenyx Pharmaceutical, GW Pharmaceuticals, Ascendis Pharma A/S, Arrowhead Pharmaceuticals and Evotec.

How do I contact PTC Therapeutics' investor relations team?

PTC Therapeutics' physical mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The biopharmaceutical company's listed phone number is 908-222-7000 and its investor relations email address is [email protected] The official website for PTC Therapeutics is www.ptcbio.com.

NASDAQ:PTCT - PTC Therapeutics Stock Price Target and Predictions

Analyst Price Target for PTCT

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of PTC Therapeutics?

What is the current price target for PTC Therapeutics?

What is the current consensus analyst rating for PTC Therapeutics?

What other companies compete with PTC Therapeutics?

How do I contact PTC Therapeutics' investor relations team?